AAPL342.56-6.65 (-1.90%) ▼|ABBV286.20+2.66 (+0.94%) ▲|ABT103.00-0.87 (-0.84%) ▼|ACN221.17+2.59 (+1.18%) ▲|ADBE217.71-3.97 (-1.79%) ▼|AMAT302.63-36.30 (-10.71%) ▼|AMD424.39-64.80 (-13.25%) ▼|AMGN435.64-0.66 (-0.15%) ▼|AMT184.21+3.06 (+1.69%) ▲|AMZN246.82-10.55 (-4.10%) ▼|AVGO304.41-42.24 (-12.19%) ▼|AXP301.70-9.41 (-3.02%) ▼|BA155.89-4.62 (-2.88%) ▼|BAC47.04-1.53 (-3.15%) ▼|BKNG144.91-2.41 (-1.64%) ▼|BLK1,101.72-34.09 (-3.00%) ▼|BMY58.80+0.46 (+0.79%) ▲|BNY141.24-3.59 (-2.48%) ▼|BRK-B570.00-2.04 (-0.36%) ▼|C110.62-4.66 (-4.04%) ▼|CAT510.45-26.92 (-5.01%) ▼|CL98.71+1.83 (+1.89%) ▲|CMCSA24.90+0.04 (+0.16%) ▲|COF178.66-3.10 (-1.71%) ▼|COP136.12+1.13 (+0.84%) ▲|COST1,102.15+8.32 (+0.76%) ▲|CRM180.62-2.69 (-1.47%) ▼|CSCO90.64-4.06 (-4.29%) ▼|CVS80.84+0.80 (+1.00%) ▲|CVX208.37+1.87 (+0.91%) ▲|DE609.25-15.64 (-2.50%) ▼|DHR220.36-7.20 (-3.16%) ▼|DIS117.98-2.27 (-1.89%) ▼|DUK129.78+0.92 (+0.71%) ▲|EMR150.93-6.67 (-4.23%) ▼|FDX303.99-10.65 (-3.38%) ▼|GD341.50-5.84 (-1.68%) ▼|GE309.62-9.26 (-2.90%) ▼|GEV699.33-56.95 (-7.53%) ▼|GILD166.43-0.10 (-0.06%) ▼|GM78.71-3.04 (-3.72%) ▼|GOOG264.00-7.02 (-2.59%) ▼|GOOGL265.29-7.37 (-2.70%) ▼|GS790.69-56.84 (-6.71%) ▼|HD339.04+2.36 (+0.70%) ▲|HON212.64-5.20 (-2.39%) ▼|IBM224.44+0.56 (+0.25%) ▲|INTC51.28-4.44 (-7.97%) ▼|INTU270.44-39.58 (-12.77%) ▼|ISRG399.05-8.19 (-2.01%) ▼|JNJ270.47+3.33 (+1.25%) ▲|JPM310.53-9.69 (-3.03%) ▼|KO96.99+0.90 (+0.94%) ▲|LIN502.83-7.38 (-1.45%) ▼|LLY1,347.11-4.01 (-0.30%) ▼|LMT565.50-6.35 (-1.11%) ▼|LOW220.84+1.70 (+0.78%) ▲|LRCX183.27-20.41 (-10.02%) ▼|MA625.59-0.91 (-0.15%) ▼|MCD273.24+0.89 (+0.33%) ▲|MDLZ66.28+0.59 (+0.90%) ▲|MDT99.94-0.67 (-0.67%) ▼|META560.84-35.38 (-5.93%) ▼|MMM177.99-0.48 (-0.27%) ▼|MO74.87+0.19 (+0.25%) ▲|MRK133.72+0.91 (+0.69%) ▲|MS165.67-9.31 (-5.32%) ▼|MSFT484.52-13.78 (-2.77%) ▼|MU594.51-95.93 (-13.89%) ▼|NEE83.45-0.34 (-0.41%) ▼|NFLX56.73-1.73 (-2.96%) ▼|NKE32.92-1.41 (-4.11%) ▼|NOW87.61-1.26 (-1.42%) ▼|NVDA125.53-20.45 (-14.01%) ▼|ORCL101.19-9.38 (-8.48%) ▼|PEP140.54+1.54 (+1.11%) ▲|PFE27.40-0.14 (-0.51%) ▼|PG169.37+1.52 (+0.91%) ▲|PLTR143.49-10.19 (-6.63%) ▼|PM184.09-2.34 (-1.26%) ▼|QCOM149.94-12.07 (-7.45%) ▼|RTX190.17-2.54 (-1.32%) ▼|SBUX103.13-1.34 (-1.28%) ▼|SCHW90.16-1.96 (-2.13%) ▼|SO93.13-0.16 (-0.17%) ▼|SPG224.35-0.87 (-0.39%) ▼|T22.31+0.46 (+2.11%) ▲|TMO669.54-19.21 (-2.79%) ▼|TMUS165.60+3.07 (+1.89%) ▲|TSLA345.82-28.59 (-7.64%) ▼|TXN263.75-22.00 (-7.70%) ▼|UBER63.47-2.13 (-3.25%) ▼|UNH339.85+9.37 (+2.84%) ▲|UNP287.29-3.34 (-1.15%) ▼|UPS106.22-2.89 (-2.65%) ▼|USB56.05-1.21 (-2.11%) ▼|V401.87-0.38 (-0.09%) ▼|VZ46.48+0.74 (+1.62%) ▲|WFC78.62-1.99 (-2.47%) ▼|WMT127.95+1.91 (+1.52%) ▲|XOM159.99+1.06 (+0.67%) ▲|AAPL342.56-6.65 (-1.90%) ▼|ABBV286.20+2.66 (+0.94%) ▲|ABT103.00-0.87 (-0.84%) ▼|ACN221.17+2.59 (+1.18%) ▲|ADBE217.71-3.97 (-1.79%) ▼|AMAT302.63-36.30 (-10.71%) ▼|AMD424.39-64.80 (-13.25%) ▼|AMGN435.64-0.66 (-0.15%) ▼|AMT184.21+3.06 (+1.69%) ▲|AMZN246.82-10.55 (-4.10%) ▼|AVGO304.41-42.24 (-12.19%) ▼|AXP301.70-9.41 (-3.02%) ▼|BA155.89-4.62 (-2.88%) ▼|BAC47.04-1.53 (-3.15%) ▼|BKNG144.91-2.41 (-1.64%) ▼|BLK1,101.72-34.09 (-3.00%) ▼|BMY58.80+0.46 (+0.79%) ▲|BNY141.24-3.59 (-2.48%) ▼|BRK-B570.00-2.04 (-0.36%) ▼|C110.62-4.66 (-4.04%) ▼|CAT510.45-26.92 (-5.01%) ▼|CL98.71+1.83 (+1.89%) ▲|CMCSA24.90+0.04 (+0.16%) ▲|COF178.66-3.10 (-1.71%) ▼|COP136.12+1.13 (+0.84%) ▲|COST1,102.15+8.32 (+0.76%) ▲|CRM180.62-2.69 (-1.47%) ▼|CSCO90.64-4.06 (-4.29%) ▼|CVS80.84+0.80 (+1.00%) ▲|CVX208.37+1.87 (+0.91%) ▲|DE609.25-15.64 (-2.50%) ▼|DHR220.36-7.20 (-3.16%) ▼|DIS117.98-2.27 (-1.89%) ▼|DUK129.78+0.92 (+0.71%) ▲|EMR150.93-6.67 (-4.23%) ▼|FDX303.99-10.65 (-3.38%) ▼|GD341.50-5.84 (-1.68%) ▼|GE309.62-9.26 (-2.90%) ▼|GEV699.33-56.95 (-7.53%) ▼|GILD166.43-0.10 (-0.06%) ▼|GM78.71-3.04 (-3.72%) ▼|GOOG264.00-7.02 (-2.59%) ▼|GOOGL265.29-7.37 (-2.70%) ▼|GS790.69-56.84 (-6.71%) ▼|HD339.04+2.36 (+0.70%) ▲|HON212.64-5.20 (-2.39%) ▼|IBM224.44+0.56 (+0.25%) ▲|INTC51.28-4.44 (-7.97%) ▼|INTU270.44-39.58 (-12.77%) ▼|ISRG399.05-8.19 (-2.01%) ▼|JNJ270.47+3.33 (+1.25%) ▲|JPM310.53-9.69 (-3.03%) ▼|KO96.99+0.90 (+0.94%) ▲|LIN502.83-7.38 (-1.45%) ▼|LLY1,347.11-4.01 (-0.30%) ▼|LMT565.50-6.35 (-1.11%) ▼|LOW220.84+1.70 (+0.78%) ▲|LRCX183.27-20.41 (-10.02%) ▼|MA625.59-0.91 (-0.15%) ▼|MCD273.24+0.89 (+0.33%) ▲|MDLZ66.28+0.59 (+0.90%) ▲|MDT99.94-0.67 (-0.67%) ▼|META560.84-35.38 (-5.93%) ▼|MMM177.99-0.48 (-0.27%) ▼|MO74.87+0.19 (+0.25%) ▲|MRK133.72+0.91 (+0.69%) ▲|MS165.67-9.31 (-5.32%) ▼|MSFT484.52-13.78 (-2.77%) ▼|MU594.51-95.93 (-13.89%) ▼|NEE83.45-0.34 (-0.41%) ▼|NFLX56.73-1.73 (-2.96%) ▼|NKE32.92-1.41 (-4.11%) ▼|NOW87.61-1.26 (-1.42%) ▼|NVDA125.53-20.45 (-14.01%) ▼|ORCL101.19-9.38 (-8.48%) ▼|PEP140.54+1.54 (+1.11%) ▲|PFE27.40-0.14 (-0.51%) ▼|PG169.37+1.52 (+0.91%) ▲|PLTR143.49-10.19 (-6.63%) ▼|PM184.09-2.34 (-1.26%) ▼|QCOM149.94-12.07 (-7.45%) ▼|RTX190.17-2.54 (-1.32%) ▼|SBUX103.13-1.34 (-1.28%) ▼|SCHW90.16-1.96 (-2.13%) ▼|SO93.13-0.16 (-0.17%) ▼|SPG224.35-0.87 (-0.39%) ▼|T22.31+0.46 (+2.11%) ▲|TMO669.54-19.21 (-2.79%) ▼|TMUS165.60+3.07 (+1.89%) ▲|TSLA345.82-28.59 (-7.64%) ▼|TXN263.75-22.00 (-7.70%) ▼|UBER63.47-2.13 (-3.25%) ▼|UNH339.85+9.37 (+2.84%) ▲|UNP287.29-3.34 (-1.15%) ▼|UPS106.22-2.89 (-2.65%) ▼|USB56.05-1.21 (-2.11%) ▼|V401.87-0.38 (-0.09%) ▼|VZ46.48+0.74 (+1.62%) ▲|WFC78.62-1.99 (-2.47%) ▼|WMT127.95+1.91 (+1.52%) ▲|XOM159.99+1.06 (+0.67%) ▲|
12.3 C
New York
Sunday, November 22, 2026

Tag: news

CALX EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds Calix (CALX) Investors of Securities Class Action Lawsuit Deadline on July 27, 2026

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Calix To Contact Him Directly To Discuss Their Options

FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch

FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum held at The Peninsula Shanghai on June 11, 2026.

Hozpitality Celebrates Hospitality Excellence at the Middle East Chef Excellence Awards, F&B Excellence Awards and Leaders Powerlist 2026

DUBAI, UAE, June 13, 2026 /PRNewswire/ -- Hozpitality Group successfully hosted the 9th Middle East Chef Excellence Awards 2026 alongside the 4th Middle East...

Hozpitality Celebrates Hospitality Excellence at the Middle East Chef Excellence Awards, F&B Excellence Awards and Leaders Powerlist 2026

DUBAI, UAE, June 13, 2026 /PRNewswire/ -- Hozpitality Group successfully hosted the 9th Middle East Chef Excellence Awards 2026 alongside the 4th Middle East...

GOOD WORKS, GIVING, AND GLAMOUR SHINE AT NORTH SHORE ANIMAL LEAGUE AMERICA’S RESCUE GALA CELEBRATING ANIMAL RESCUE AND ADOPTION

Attendees Included Event Chairperson Beth Stern, Event Host Will Ganss, Event Entertainer Joshua Radin, Liz Gillies, The Dogist (Elias Weiss Friedman,) and Others.  Proceeds...

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

AIFA 就涉及 HyalRoute Communication Group Limited 的股份收購交易正式作出澄清及反駁

紐約, June 13, 2026 (GLOBE NEWSWIRE) -- All In FutureTech Alliance Inc. (Nasdaq: AIFA)(「公司」或「AIFA」)近日發現,HyalRoute Communication Group Limited(「HyalRoute」)的現任管理團隊以 Dong 女士個人名義,並透過若干柬埔寨媒體及社交媒體渠道,發表或轉發言論,指公司於 2026 年 5 月 22 日有關收購 HyalRoute 控股權益的公告屬「虛假」或「捏造」。

New TALVEY®▼(talquetamab) plus daratumumab data demonstrate the potential strength of a novel bispecific combination in earlier-line relapsed or refractory multiple myeloma

BEERSE, BELGIUM, June 13, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced results from the investigational Phase 3 MonumenTAL-3 study.1 The results showed that TALVEY® (talquetamab), a GPRC5D bispecific antibody, in combination with daratumumab with or without pomalidomide demonstrated significant reduction in the risk of disease progression or death of up to 72.0%, and clinically meaningful reduction of up to 53.0% in the risk of death, compared to the standard regimen of daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma (RRMM).1 Results showed a progression-free survival (PFS) rate of up to 81.3% versus standard of care (51.2%) and an overall survival (OS) rate of up to 89.2% versus standard of care (79.1%) at 24 months.1  

New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myeloma

TALVEY® plus DARZALEX FASPRO® with or without pomalidomide showed progression-free survival of up to 81% and overall survival of up to 89% at 24 monthsMonumenTAL-3 is the...

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies , a global provider of IT solutions and services, today opened a...

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies , a global provider of IT solutions and services, today opened a...

FREELANDER 8 Makes First Public Appearance Ahead of Official Abu Dhabi Launch

FREELANDER 8 made its first public appearance at the Abu Dhabi Investment Forum held at The Peninsula Shanghai on June 11, 2026.

Innoscience Secures Final Victory in Patent Lawsuit as China’s Supreme Court Upholds Injunction Against Infineon GaN Products

SUZHOU, China, June 13, 2026 /PRNewswire/ -- In a landmark decision for the global semiconductor industry, the Supreme People's Court of China has officially...

Innoscience Secures Final Victory in Patent Lawsuit as China’s Supreme Court Upholds Injunction Against Infineon GaN Products

SUZHOU, China, June 13, 2026 /PRNewswire/ -- In a landmark decision for the global semiconductor industry, the Supreme People's Court of China has officially...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsNews